Indication
Delay or failure of allogenic bone marrow transplant
Delay or failure of allogeneic bone marrow transplant is a life-threatening hematologic complication in patients who undergo allogeneic bone marrow or hematopoietic stem cell transplantation. Read more about Delay or failure of allogenic bone marrow transplant
3 drugs 3 manufacturers
Drugs that treat it
Common Delay or failure of allogenic bone marrow transplant therapies.
LEUKINE (sargramostim)
LEUKINE (sargramostim)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonDelay or failure of allogeneic bone marrow transplant is a life-threatening hematologic complication in patients who undergo allogeneic bone marrow or hematopoietic stem cell transplantation.
It encompasses both primary graft failure, characterized by the prolonged absence of donor stem cell engraftment and sustained severe pancytopenia by day 28 to 42 post-transplant, and secondary graft failure, marked by a subsequent loss of donor hematopoiesis after initial successful engraftment.
Pathophysiologically, this clinical state is driven by immune-mediated host rejection, insufficient donor cell dose, poor graft function, or adverse microenvironmental factors such as opportunistic viral infections and drug toxicities, predisposing patients to severe infectious and hemorrhagic mortality.
- transplants.org
Delay or failure of allogeneic bone marrow transplant is a life-threatening hematologic complication in patients who undergo allogeneic bone marrow or hematopoietic stem cell transplantation It encompasses both primary graft failure, characterized by the prolonged absence of donor stem cell engraftment and sustained severe pancytopenia by day 28 to 42 post-transplant, and secondary graft failure, marked by a subsequent loss of donor hematopoiesis after initial successful engraftment Pathophysiol...
- nih.gov
Delay or failure of allogeneic bone marrow transplant is a life-threatening hematologic complication in patients who undergo allogeneic bone marrow or hematopoietic stem cell transplantation
- nih.gov
It encompasses both primary graft failure, characterized by the prolonged absence of donor stem cell engraftment and sustained severe pancytopenia by day 28 to 42 post-transplant, and secondary graft failure, marked by a subsequent loss of donor hematopoiesis after initial successful engraftment Pathophysiologically, this clinical state is driven by immune-mediated host rejection, insufficient donor cell dose, poor graft function, or adverse microenvironmental factors such as opportunistic viral...
Personalize your experience
Follow Delay or failure of allogenic bone marrow transplant and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.